Central Nervous System Biomarkers Market Growth Trajectory Through 2024-2033

Spread the love

The Central Nervous System Biomarkers Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Central Nervous System Biomarkers Market:

https://www.thebusinessresearchcompany.com/report/central-nervous-system-biomarkers-global-market-report

According to The Business Research Company’s Central Nervous System Biomarkers Global Market Report 2024, The central nervous system biomarkers market size has grown rapidly in recent years. It will grow from $5.01 billion in 2023 to $5.55 billion in 2024 at a compound annual growth rate (CAGR) of 10.8%. The growth in the historic period can be attributed to rise in concerns regarding neurological disorders, high prevalence of central nervous system illnesses, growth in demand for enhanced diagnosis and treatment, improved healthcare infrastructure, rise in aging population.

The central nervous system biomarkers market size is expected to see strong growth in the next few years. It will grow to $8.02 billion in 2028 at a compound annual growth rate (CAGR) of 9.7%. The growth in the forecast period can be attributed to increasing prevalence of neurological disorders, growing demand for personalized medicine, rising geriatric population, increasing focus on early diagnosis, growing demand for non-invasive diagnostic tools. Major trends in the forecast period include new technological advancements, strategic collaborations between biotechnology companies, pharmaceutical companies, and other stakeholders, growth in research on cerebrospinal fluid (csf) and blood-based biomarkers, utilization of ai and machine learning algorithms.

The rise in neurological illnesses is expected to propel the growth of the central nervous system biomarker market going forward. Neurological illnesses, also known as neurological disorders, refer to a broad range of conditions that affect the brain, spinal cord, and nerves throughout the body. These disorders can arise from various causes, including genetic factors, infections, autoimmune responses, degenerative processes, tumors, vascular issues, and traumatic injuries. In neurological disorders, central nervous system (CNS) biomarkers aid clinical diagnosis, determine illness risk or prognosis, assess disease stage, and track treatment response. They play a significant role in understanding these diseases and their ability to be treated. For instance, in April 2023, according to the Centers for Disease Control and Prevention, a US-based government agency, Alzheimer’s disease affected an estimated 6.7 million Americans aged 65 and older. This number is expected to nearly triple to 14 million by 2060. Moreover, the number of people living with the disease doubles every five years after age 65. Therefore, the rise in neurological illnesses drives the growth of the central nervous system biomarker market.

Get A Free Sample Of The Report (Includes Graphs And Tables):

https://www.thebusinessresearchcompany.com/sample.aspx?id=12632&type=smp

The central nervous system biomarkers market covered in this report is segmented –

1) By Type: Safety Biomarker, Efficacy Biomarker, Validation Biomarker, Other Types

2) By Disease: Multiple Sclerosis, Alzheimer’s Disease, Parkinson’s Disease, Traumatic Brain Injury, Other Diseases

3) By Application: Drug Discovery And Development, Personalized Medicines, Disease Risk Assessment, Diagnostics, Other Applications

4) By End-Users: Diagnostic Labs, Clinics, Hospitals, Research Centers, Other End-Users

Innovative drug approvals are a key trend gaining popularity in the central nervous system biomarker market. Major companies operating in the central nervous system biomarkers market are focused on developing innovative drugs and getting approval to strengthen their position in the market. For instance, in January 2022, Denovo Biopharma LLC, a US-based clinical-stage biopharmaceutical company, announced the US Food and Drug Administration’s (FDA) approval and authorization of the company’s investigational new drug (IND) application of DB104 (liafensine) for the treatment of treatment-resistant depression (TRD). It is the first biomarker-guided global CNS clinical trial for TRD. Additionally, it could help identify patients who are more likely to respond to liafensine, which could lead to more personalized treatment decisions. Liafensine is a novel compound that works by increasing levels of dopamine and norepinephrine in the brain.

The central nervous system biomarkers market report table of contents includes: